Search Results - Roadcap, Lori T

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Considerations in the development of circulating tumor cell technology for clinical use

    Considerations in the development of circulating tumor cell technology for clinical use by Parkinson, David R, Dracopoli, Nicholas, Petty, Brenda Gumbs, Compton, Carolyn, Cristofanilli, Massimo, Deisseroth, Albert, Hayes, Daniel F, Kapke, Gordon, Kumar, Prasanna, Lee, Jerry Sh, Liu, Minetta C, McCormack, Robert, Mikulski, Stanislaw, Nagahara, Larry, Pantel, Klaus, Pearson-White, Sonia, Punnoose, Elizabeth A, Roadcap, Lori T, Schade, Andrew E, Scher, Howard I, Sigman, Caroline C, Kelloff, Gary J

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

    Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial by Falchook, Gerald S, Dr, Lewis, Karl D, MD, Infante, Jeffrey R, MD, Gordon, Michael S, MD, Vogelzang, Nicholas J, MD, DeMarini, Douglas J, PhD, Sun, Peng, PhD, Moy, Christopher, MS, Szabo, Stephen A, BA, Roadcap, Lori T, MS, Peddareddigari, Vijay GR, MD, Lebowitz, Peter F, MD, Le, Ngocdiep T, MD, Burris, Howard A, MD, Messersmith, Wells A, MD, O'Dwyer, Peter J, Prof, Kim, Kevin B, MD, Flaherty, Keith, MD, Bendell, Johanna C, MD, Gonzalez, Rene, Prof, Kurzrock, Razelle, Prof, Fecher, Leslie A, MD

    Published in The lancet oncology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Abstract 1752: A phase I/IIa, first time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency

    Abstract 1752: A phase I/IIa, first time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency by Blackman, Samuel C., Gainer, Shelby D., Suttle, Benjamin B., Skordos, Konstantine W., Greshock, Joel D., Motwani, Monica, Roadcap, Lori T., Hardwicke, Mary Ann A., Wooster, Richard F.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial

    Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial by Falchook, Gerald S, Lewis, Karl D, Infante, Jeffrey R, Gordon, Michael S, Vogelzang, Nicholas J, DeMarini, Douglas J, Sun, Peng, Moy, Christopher, Szabo, Stephen A., Roadcap, Lori T, Peddareddigari, Vijay G R, Lebowitz, Peter F, Le, Ngocdiep T, Burris, Howard A, Messersmith, Wells A, O'Dwyer, Peter J, Kim, Kevin B., Flaherty, Keith, Bendell, Johanna C., Gonzalez, Rene, Kurzrock, Razelle, Fecher, Leslie A

    Published in The lancet oncology
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS

    Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS by Perlin, David S, Zafir-Lavie, Inbal, Roadcap, Lori, Raines, Shane, Ware, Carl F, Neil, Garry A

    Published in mSphere
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS

    Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS by David S. Perlin, Inbal Zafir-Lavie, Lori Roadcap, Shane Raines, Carl F. Ware, Garry A. Neil

    Published in mSphere
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: